JP5529876B2 - Mmp−13阻害剤として有用なヘテロアリール置換インドール化合物 - Google Patents
Mmp−13阻害剤として有用なヘテロアリール置換インドール化合物 Download PDFInfo
- Publication number
- JP5529876B2 JP5529876B2 JP2011532175A JP2011532175A JP5529876B2 JP 5529876 B2 JP5529876 B2 JP 5529876B2 JP 2011532175 A JP2011532175 A JP 2011532175A JP 2011532175 A JP2011532175 A JP 2011532175A JP 5529876 B2 JP5529876 B2 JP 5529876B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- methyl
- alkoxy
- mmol
- esi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100027995 Collagenase 3 Human genes 0.000 title description 19
- 108050005238 Collagenase 3 Proteins 0.000 title description 18
- 239000003112 inhibitor Substances 0.000 title description 6
- 150000002475 indoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 88
- 125000000217 alkyl group Chemical group 0.000 claims description 77
- -1 cyano, hydroxyl Chemical group 0.000 claims description 65
- 125000003545 alkoxy group Chemical group 0.000 claims description 39
- 229910052736 halogen Inorganic materials 0.000 claims description 31
- 150000002367 halogens Chemical class 0.000 claims description 31
- 125000002252 acyl group Chemical group 0.000 claims description 25
- 125000004076 pyridyl group Chemical group 0.000 claims description 23
- 125000004442 acylamino group Chemical group 0.000 claims description 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- 125000002883 imidazolyl group Chemical group 0.000 claims description 17
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 13
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 13
- 125000002971 oxazolyl group Chemical group 0.000 claims description 13
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 12
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 11
- 125000000335 thiazolyl group Chemical group 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000008482 osteoarthritis Diseases 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000001245 periodontitis Diseases 0.000 claims description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 3
- 150000003462 sulfoxides Chemical class 0.000 claims description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 144
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 62
- 239000000243 solution Substances 0.000 description 52
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 49
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 44
- 239000011541 reaction mixture Substances 0.000 description 44
- 239000000203 mixture Substances 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
- 238000006243 chemical reaction Methods 0.000 description 37
- 239000011734 sodium Substances 0.000 description 37
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- 239000012267 brine Substances 0.000 description 28
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 28
- 239000000047 product Substances 0.000 description 27
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000007787 solid Substances 0.000 description 24
- 238000000034 method Methods 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 19
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 18
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 18
- 239000000377 silicon dioxide Substances 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 239000003480 eluent Substances 0.000 description 17
- 239000003921 oil Substances 0.000 description 17
- 239000012044 organic layer Substances 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 229910052786 argon Inorganic materials 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- 239000012043 crude product Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- IQTHEAQKKVAXGV-UHFFFAOYSA-N 4-ditert-butylphosphanyl-n,n-dimethylaniline Chemical compound CN(C)C1=CC=C(P(C(C)(C)C)C(C)(C)C)C=C1 IQTHEAQKKVAXGV-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 8
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 102000000503 Collagen Type II Human genes 0.000 description 7
- 108010041390 Collagen Type II Proteins 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 238000004007 reversed phase HPLC Methods 0.000 description 7
- 229910052717 sulfur Chemical group 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- LXKOPLOWPKRFDQ-UHFFFAOYSA-N 4-bromo-5-methyl-n-(pyridin-4-ylmethyl)-1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxamide Chemical compound C[Si](C)(C)CCOCN1C(C)=C(Br)N=C1C(=O)NCC1=CC=NC=C1 LXKOPLOWPKRFDQ-UHFFFAOYSA-N 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 235000011056 potassium acetate Nutrition 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- USASUEYARBQNBM-UHFFFAOYSA-N 1h-indol-2-ylboronic acid Chemical compound C1=CC=C2NC(B(O)O)=CC2=C1 USASUEYARBQNBM-UHFFFAOYSA-N 0.000 description 3
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2,5-dimethylpyridine Chemical compound CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 3
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 3
- WNCROGXBCWASJW-UHFFFAOYSA-N 5-methyl-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]-1H-imidazole-2-carboxylic acid Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C2=C(NC(=N2)C(O)=O)C)=N1 WNCROGXBCWASJW-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 3
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 238000006069 Suzuki reaction reaction Methods 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000006242 amine protecting group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- ZIYWMZOPRZCRSX-UHFFFAOYSA-N tert-butyl 2-(3-methyl-1,2,4-oxadiazol-5-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indole-1-carboxylate Chemical compound CC1=NOC(C=2N(C3=CC=C(C=C3C=2)B2OC(C)(C)C(C)(C)O2)C(=O)OC(C)(C)C)=N1 ZIYWMZOPRZCRSX-UHFFFAOYSA-N 0.000 description 3
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 3
- 210000000626 ureter Anatomy 0.000 description 3
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
- XWVNWTPTHXKLJR-UHFFFAOYSA-N 1-bromo-5-methylimidazole Chemical compound CC1=CN=CN1Br XWVNWTPTHXKLJR-UHFFFAOYSA-N 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- FBAFUQTUOZGHGJ-UHFFFAOYSA-N 1-methyl-5-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]pyrazole-3-carboxylic acid Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C=2N(N=C(C=2)C(O)=O)C)=N1 FBAFUQTUOZGHGJ-UHFFFAOYSA-N 0.000 description 2
- KFEWUCOFCOAYQZ-UHFFFAOYSA-N 2,5-dimethyl-1-oxidopyridin-1-ium Chemical compound CC1=CC=C(C)[N+]([O-])=C1 KFEWUCOFCOAYQZ-UHFFFAOYSA-N 0.000 description 2
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
- UHHFYGOUQISNPH-UHFFFAOYSA-N 2-[4-[[[5-(2-ethoxycarbonyl-1h-indol-5-yl)-1-methylpyrazole-3-carbonyl]amino]methyl]phenyl]acetic acid Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(N(N=1)C)=CC=1C(=O)NCC1=CC=C(CC(O)=O)C=C1 UHHFYGOUQISNPH-UHFFFAOYSA-N 0.000 description 2
- GPBRXFWIPQNWNB-UHFFFAOYSA-N 4,5-dibromo-1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxylic acid Chemical compound C[Si](C)(C)CCOCN1C(Br)=C(Br)N=C1C(O)=O GPBRXFWIPQNWNB-UHFFFAOYSA-N 0.000 description 2
- LFIWXXXFJFOECP-UHFFFAOYSA-N 4-(aminomethyl)benzonitrile Chemical compound NCC1=CC=C(C#N)C=C1 LFIWXXXFJFOECP-UHFFFAOYSA-N 0.000 description 2
- HPBSGHQXVPAVMT-UHFFFAOYSA-N 4-[[[5-[2-(2-fluoropyridin-4-yl)-1h-indol-5-yl]-1-methylpyrazole-3-carbonyl]amino]methyl]benzoic acid Chemical compound CN1N=C(C(=O)NCC=2C=CC(=CC=2)C(O)=O)C=C1C(C=C1C=2)=CC=C1NC=2C1=CC=NC(F)=C1 HPBSGHQXVPAVMT-UHFFFAOYSA-N 0.000 description 2
- KMLUNXYSVVORJO-UHFFFAOYSA-N 4-[[[5-[2-(4,5-dihydro-1,3-oxazol-2-yl)-1h-indol-5-yl]-1-methylpyrazole-3-carbonyl]amino]methyl]benzoic acid Chemical compound CN1N=C(C(=O)NCC=2C=CC(=CC=2)C(O)=O)C=C1C(C=C1C=2)=CC=C1NC=2C1=NCCO1 KMLUNXYSVVORJO-UHFFFAOYSA-N 0.000 description 2
- MOKOYWUWOZIRMJ-UHFFFAOYSA-N 4-[[[5-methyl-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]pyridine-2-carbonyl]amino]methyl]benzoic acid Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C=2C(=CN=C(C=2)C(=O)NCC=2C=CC(=CC=2)C(O)=O)C)=N1 MOKOYWUWOZIRMJ-UHFFFAOYSA-N 0.000 description 2
- KJUFDFDLMYPVFN-UHFFFAOYSA-N 4-bromo-5-methyl-1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxylic acid Chemical compound CC1=C(Br)N=C(C(O)=O)N1COCC[Si](C)(C)C KJUFDFDLMYPVFN-UHFFFAOYSA-N 0.000 description 2
- DWOZNANUEDYIOF-UHFFFAOYSA-L 4-ditert-butylphosphanyl-n,n-dimethylaniline;dichloropalladium Chemical compound Cl[Pd]Cl.CN(C)C1=CC=C(P(C(C)(C)C)C(C)(C)C)C=C1.CN(C)C1=CC=C(P(C(C)(C)C)C(C)(C)C)C=C1 DWOZNANUEDYIOF-UHFFFAOYSA-L 0.000 description 2
- MJNYXIVXCDSLLA-UHFFFAOYSA-N 5-(5-bromo-1H-indol-2-yl)-3-methyl-1,2,4-oxadiazole Chemical compound CC1=NOC(C=2NC3=CC=C(Br)C=C3C=2)=N1 MJNYXIVXCDSLLA-UHFFFAOYSA-N 0.000 description 2
- SJCVIFOMQDAVPH-UHFFFAOYSA-N 5-[2-(pyridin-4-ylmethylcarbamoyl)pyridin-4-yl]-1h-indole-2-carboxylic acid Chemical compound C=1C=C2NC(C(=O)O)=CC2=CC=1C(C=1)=CC=NC=1C(=O)NCC1=CC=NC=C1 SJCVIFOMQDAVPH-UHFFFAOYSA-N 0.000 description 2
- YAULOOYNCJDPPU-UHFFFAOYSA-N 5-bromo-1h-indole-2-carboxylic acid Chemical compound BrC1=CC=C2NC(C(=O)O)=CC2=C1 YAULOOYNCJDPPU-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102100030411 Neutrophil collagenase Human genes 0.000 description 2
- 101710118230 Neutrophil collagenase Proteins 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- DCBDOYDVQJVXOH-UHFFFAOYSA-N azane;1h-indole Chemical compound N.C1=CC=C2NC=CC2=C1 DCBDOYDVQJVXOH-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 230000011382 collagen catabolic process Effects 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- GTIUUFDCOLSPJI-UHFFFAOYSA-N ethyl 3-fluoro-5-[5-methyl-2-(pyridin-4-ylmethylcarbamoyl)-1h-imidazol-4-yl]-1h-indole-2-carboxylate Chemical compound C1=C2C(F)=C(C(=O)OCC)NC2=CC=C1C(=C(N=1)C)NC=1C(=O)NCC1=CC=NC=C1 GTIUUFDCOLSPJI-UHFFFAOYSA-N 0.000 description 2
- AFYVYYBYQDUIRR-UHFFFAOYSA-N ethyl 4-bromo-5-methyl-1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxylate Chemical compound CCOC(=O)C1=NC(Br)=C(C)N1COCC[Si](C)(C)C AFYVYYBYQDUIRR-UHFFFAOYSA-N 0.000 description 2
- IUJWPHRXZDQSQS-UHFFFAOYSA-N ethyl 5-[4-[(4-fluoro-3-methylphenyl)methylcarbamoyl]pyrimidin-2-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(N=1)=NC=CC=1C(=O)NCC1=CC=C(F)C(C)=C1 IUJWPHRXZDQSQS-UHFFFAOYSA-N 0.000 description 2
- OVZZLYJFJOWMTM-UHFFFAOYSA-N ethyl 5-[5-[(2,4-dimethoxyphenyl)methylcarbamoyl]-4-methylthiophen-3-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(C=1C)=CSC=1C(=O)NCC1=CC=C(OC)C=C1OC OVZZLYJFJOWMTM-UHFFFAOYSA-N 0.000 description 2
- LWRLKENDQISGEU-UHFFFAOYSA-N ethyl 5-bromo-1h-indole-2-carboxylate Chemical compound BrC1=CC=C2NC(C(=O)OCC)=CC2=C1 LWRLKENDQISGEU-UHFFFAOYSA-N 0.000 description 2
- BDFZWTJIAHZKMB-UHFFFAOYSA-N ethyl 5-bromo-1h-pyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound BrC1=CN=C2NC(C(=O)OCC)=CC2=C1 BDFZWTJIAHZKMB-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- FCRCTHGEYAIIIU-UHFFFAOYSA-N methyl 5-bromo-1-methylpyrazole-3-carboxylate Chemical compound COC(=O)C=1C=C(Br)N(C)N=1 FCRCTHGEYAIIIU-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- TXQWFIVRZNOPCK-UHFFFAOYSA-N pyridin-4-ylmethanamine Chemical compound NCC1=CC=NC=C1 TXQWFIVRZNOPCK-UHFFFAOYSA-N 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
- GMFOJDNVEZWBLW-UHFFFAOYSA-N (4-chloro-5-methylpyridin-2-yl)methyl acetate Chemical compound CC(=O)OCC1=CC(Cl)=C(C)C=N1 GMFOJDNVEZWBLW-UHFFFAOYSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- PRIGFEJKMMRJSF-UHFFFAOYSA-M 1-fluoro-2,4,6-trimethylpyridin-1-ium;trifluoromethanesulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)F.CC1=CC(C)=[N+](F)C(C)=C1 PRIGFEJKMMRJSF-UHFFFAOYSA-M 0.000 description 1
- DYQIYXDSKUUZRI-UHFFFAOYSA-N 1-fluoro-4-iodo-2-methylbenzene Chemical compound CC1=CC(I)=CC=C1F DYQIYXDSKUUZRI-UHFFFAOYSA-N 0.000 description 1
- HRWBJLDZMJDSLD-UHFFFAOYSA-N 1-o-tert-butyl 2-o-ethyl 2h-pyridine-1,2-dicarboxylate Chemical compound CCOC(=O)C1C=CC=CN1C(=O)OC(C)(C)C HRWBJLDZMJDSLD-UHFFFAOYSA-N 0.000 description 1
- QNZSGQVIHWDDCU-UHFFFAOYSA-N 1-o-tert-butyl 2-o-ethyl 5-bromoindole-1,2-dicarboxylate Chemical compound BrC1=CC=C2N(C(=O)OC(C)(C)C)C(C(=O)OCC)=CC2=C1 QNZSGQVIHWDDCU-UHFFFAOYSA-N 0.000 description 1
- JLSDTBMDJLUONX-UHFFFAOYSA-N 1-o-tert-butyl 2-o-ethyl 5-bromopyrrolo[3,2-b]pyridine-1,2-dicarboxylate Chemical compound BrC1=CC=C2N(C(=O)OC(C)(C)C)C(C(=O)OCC)=CC2=N1 JLSDTBMDJLUONX-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- JCGGPCDDFXIVQB-UHFFFAOYSA-N 2,4,5-tribromo-1h-imidazole Chemical compound BrC1=NC(Br)=C(Br)N1 JCGGPCDDFXIVQB-UHFFFAOYSA-N 0.000 description 1
- GVGSFHVUBRWBJT-UHFFFAOYSA-N 2,5-dimethyl-4-nitro-1-oxidopyridin-1-ium Chemical compound CC1=C[N+]([O-])=C(C)C=C1[N+]([O-])=O GVGSFHVUBRWBJT-UHFFFAOYSA-N 0.000 description 1
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- FJFOHMQRTFMHGF-UHFFFAOYSA-N 3-(2-pyridin-4-yl-1h-indol-5-yl)-n-(pyridin-4-ylmethyl)benzamide Chemical compound C=1C=CC(C=2C=C3C=C(NC3=CC=2)C=2C=CN=CC=2)=CC=1C(=O)NCC1=CC=NC=C1 FJFOHMQRTFMHGF-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QYMGLQOXQHLDAR-UHFFFAOYSA-N 4,5-dibromo-n-(pyridin-4-ylmethyl)-1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxamide Chemical compound C[Si](C)(C)CCOCN1C(Br)=C(Br)N=C1C(=O)NCC1=CC=NC=C1 QYMGLQOXQHLDAR-UHFFFAOYSA-N 0.000 description 1
- ZNDZJTJFMBHECO-UHFFFAOYSA-N 4-(2-pyridin-4-yl-1h-indol-5-yl)-n-(pyridin-4-ylmethyl)pyridine-2-carboxamide Chemical compound C=1C(C=2C=C3C=C(NC3=CC=2)C=2C=CN=CC=2)=CC=NC=1C(=O)NCC1=CC=NC=C1 ZNDZJTJFMBHECO-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- NYFXGSUDNSAOLU-UHFFFAOYSA-N 4-[2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]-5-methyl-N-(pyridin-4-ylmethyl)-1H-imidazole-2-carboxamide Chemical compound CC=1NC(C(=O)NCC=2C=CN=CC=2)=NC=1C(C=C1C=2)=CC=C1NC=2C(ON=1)=NC=1C1CC1 NYFXGSUDNSAOLU-UHFFFAOYSA-N 0.000 description 1
- LMAXNMCABVPYQS-UHFFFAOYSA-N 4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]-N-(pyridin-4-ylmethyl)pyridine-2-carboxamide Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C=2C=C(N=CC=2)C(=O)NCC=2C=CN=CC=2)=N1 LMAXNMCABVPYQS-UHFFFAOYSA-N 0.000 description 1
- MJQABAMIWJYXDR-UHFFFAOYSA-N 4-[[(5-bromo-1-methylpyrazole-3-carbonyl)amino]methyl]benzoic acid Chemical compound C1=C(Br)N(C)N=C1C(=O)NCC1=CC=C(C(O)=O)C=C1 MJQABAMIWJYXDR-UHFFFAOYSA-N 0.000 description 1
- IFTRAWSZKLIIEY-UHFFFAOYSA-N 4-[[[1-methyl-5-(2-pyridin-3-yl-1h-indol-5-yl)pyrazole-3-carbonyl]amino]methyl]benzoic acid Chemical compound CN1N=C(C(=O)NCC=2C=CC(=CC=2)C(O)=O)C=C1C(C=C1C=2)=CC=C1NC=2C1=CC=CN=C1 IFTRAWSZKLIIEY-UHFFFAOYSA-N 0.000 description 1
- KHBDSUQMGXRFJV-UHFFFAOYSA-N 4-[[[1-methyl-5-(2-pyridin-4-yl-1h-indol-5-yl)pyrazole-3-carbonyl]amino]methyl]benzoic acid Chemical compound CN1N=C(C(=O)NCC=2C=CC(=CC=2)C(O)=O)C=C1C(C=C1C=2)=CC=C1NC=2C1=CC=NC=C1 KHBDSUQMGXRFJV-UHFFFAOYSA-N 0.000 description 1
- LQGGGMNYWAAXAT-UHFFFAOYSA-N 4-[[[1-methyl-5-(2-pyrimidin-2-yl-1h-indol-5-yl)pyrazole-3-carbonyl]amino]methyl]benzoic acid Chemical compound CN1N=C(C(=O)NCC=2C=CC(=CC=2)C(O)=O)C=C1C(C=C1C=2)=CC=C1NC=2C1=NC=CC=N1 LQGGGMNYWAAXAT-UHFFFAOYSA-N 0.000 description 1
- YMHMIBRQTUFFNZ-UHFFFAOYSA-N 4-[[[1-methyl-5-(2-pyrimidin-5-yl-1h-indol-5-yl)pyrazole-3-carbonyl]amino]methyl]benzoic acid Chemical compound CN1N=C(C(=O)NCC=2C=CC(=CC=2)C(O)=O)C=C1C(C=C1C=2)=CC=C1NC=2C1=CN=CN=C1 YMHMIBRQTUFFNZ-UHFFFAOYSA-N 0.000 description 1
- ZKUUWCIMRRJHMV-UHFFFAOYSA-N 4-[[[1-methyl-5-[2-(1-methylpyrazol-4-yl)-1h-indol-5-yl]pyrazole-3-carbonyl]amino]methyl]benzoic acid Chemical compound C1=NN(C)C=C1C1=CC2=CC(C=3N(N=C(C=3)C(=O)NCC=3C=CC(=CC=3)C(O)=O)C)=CC=C2N1 ZKUUWCIMRRJHMV-UHFFFAOYSA-N 0.000 description 1
- BFTMMWIOZBKLSX-UHFFFAOYSA-N 4-[[[1-methyl-5-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]pyrazole-3-carbonyl]amino]methyl]benzoic acid Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C=2N(N=C(C=2)C(=O)NCC=2C=CC(=CC=2)C(O)=O)C)=N1 BFTMMWIOZBKLSX-UHFFFAOYSA-N 0.000 description 1
- ZKWIVWMUPDDWHD-UHFFFAOYSA-N 4-[[[4-(2-ethoxycarbonyl-1h-indol-5-yl)pyridine-2-carbonyl]amino]methyl]benzoic acid Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(C=1)=CC=NC=1C(=O)NCC1=CC=C(C(O)=O)C=C1 ZKWIVWMUPDDWHD-UHFFFAOYSA-N 0.000 description 1
- WNXWHPFRWGDHSF-UHFFFAOYSA-N 4-[[[4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]pyridine-2-carbonyl]amino]methyl]benzoic acid Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C=2C=C(N=CC=2)C(=O)NCC=2C=CC(=CC=2)C(O)=O)=N1 WNXWHPFRWGDHSF-UHFFFAOYSA-N 0.000 description 1
- FOIUQQUDMFDDDC-UHFFFAOYSA-N 4-[[[5-(1h-indol-5-yl)-1-methylpyrazole-3-carbonyl]amino]methyl]benzoic acid Chemical compound C1=C(C=2C=C3C=CNC3=CC=2)N(C)N=C1C(=O)NCC1=CC=C(C(O)=O)C=C1 FOIUQQUDMFDDDC-UHFFFAOYSA-N 0.000 description 1
- MTGCEAYTDNXZMD-UHFFFAOYSA-N 4-[[[5-(2-cyano-1h-indol-5-yl)-1-methylpyrazole-3-carbonyl]amino]methyl]benzoic acid Chemical compound C1=C(C=2C=C3C=C(NC3=CC=2)C#N)N(C)N=C1C(=O)NCC1=CC=C(C(O)=O)C=C1 MTGCEAYTDNXZMD-UHFFFAOYSA-N 0.000 description 1
- ACLRHOGMULWJLC-UHFFFAOYSA-N 4-[[[5-[2-(2-fluoro-6-methylpyridin-4-yl)-1h-indol-5-yl]-1-methylpyrazole-3-carbonyl]amino]methyl]benzoic acid Chemical compound FC1=NC(C)=CC(C=2NC3=CC=C(C=C3C=2)C=2N(N=C(C=2)C(=O)NCC=2C=CC(=CC=2)C(O)=O)C)=C1 ACLRHOGMULWJLC-UHFFFAOYSA-N 0.000 description 1
- CDVWURIEQQDWHD-UHFFFAOYSA-N 4-[[[5-[2-(4-fluoro-3-methylphenyl)-1h-indol-5-yl]-1-methylpyrazole-3-carbonyl]amino]methyl]benzoic acid Chemical compound C1=C(F)C(C)=CC(C=2NC3=CC=C(C=C3C=2)C=2N(N=C(C=2)C(=O)NCC=2C=CC(=CC=2)C(O)=O)C)=C1 CDVWURIEQQDWHD-UHFFFAOYSA-N 0.000 description 1
- POQKRVUUGMTRAA-UHFFFAOYSA-N 4-[[[5-[2-(6-fluoropyridin-3-yl)-1h-indol-5-yl]-1-methylpyrazole-3-carbonyl]amino]methyl]benzoic acid Chemical compound CN1N=C(C(=O)NCC=2C=CC(=CC=2)C(O)=O)C=C1C(C=C1C=2)=CC=C1NC=2C1=CC=C(F)N=C1 POQKRVUUGMTRAA-UHFFFAOYSA-N 0.000 description 1
- MPAWABYIQDNGTF-UHFFFAOYSA-N 4-[[[5-[2-(ethoxymethyl)-1h-indol-5-yl]-1-methylpyrazole-3-carbonyl]amino]methyl]benzoic acid Chemical compound C=1C=C2NC(COCC)=CC2=CC=1C(N(N=1)C)=CC=1C(=O)NCC1=CC=C(C(O)=O)C=C1 MPAWABYIQDNGTF-UHFFFAOYSA-N 0.000 description 1
- SIWRYLIWZMXAPS-UHFFFAOYSA-N 4-[[[5-[2-(hydroxymethyl)-1h-indol-5-yl]-1-methylpyrazole-3-carbonyl]amino]methyl]benzoic acid Chemical compound C1=C(C=2C=C3C=C(CO)NC3=CC=2)N(C)N=C1C(=O)NCC1=CC=C(C(O)=O)C=C1 SIWRYLIWZMXAPS-UHFFFAOYSA-N 0.000 description 1
- FEOAPZFVHTZRHS-UHFFFAOYSA-N 4-[[[5-methyl-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]-1H-imidazole-2-carbonyl]amino]methyl]benzoic acid Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C2=C(NC(=N2)C(=O)NCC=2C=CC(=CC=2)C(O)=O)C)=N1 FEOAPZFVHTZRHS-UHFFFAOYSA-N 0.000 description 1
- PMZQNZNCSVAOSD-UHFFFAOYSA-N 4-bromo-n-[(4-cyanophenyl)methyl]-5-methyl-1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxamide Chemical compound C[Si](C)(C)CCOCN1C(C)=C(Br)N=C1C(=O)NCC1=CC=C(C#N)C=C1 PMZQNZNCSVAOSD-UHFFFAOYSA-N 0.000 description 1
- WKOZZJRWYNIQJB-UHFFFAOYSA-N 4-chloro-2,5-dimethyl-1-oxidopyridin-1-ium Chemical compound CC1=C[N+]([O-])=C(C)C=C1Cl WKOZZJRWYNIQJB-UHFFFAOYSA-N 0.000 description 1
- CNAVZNPDBKLQMF-UHFFFAOYSA-N 5-[5-[(4-carboxyphenyl)methylcarbamoyl]-2-methylpyrazol-3-yl]-1h-indole-2-carboxylic acid Chemical compound C1=C(C=2C=C3C=C(NC3=CC=2)C(O)=O)N(C)N=C1C(=O)NCC1=CC=C(C(O)=O)C=C1 CNAVZNPDBKLQMF-UHFFFAOYSA-N 0.000 description 1
- YWMQGAQDZQJWSV-UHFFFAOYSA-N 5-bromo-1-methyl-n-(pyridin-4-ylmethyl)pyrazole-3-carboxamide Chemical compound C1=C(Br)N(C)N=C1C(=O)NCC1=CC=NC=C1 YWMQGAQDZQJWSV-UHFFFAOYSA-N 0.000 description 1
- QLYDIHRYOAQXJT-UHFFFAOYSA-N 5-bromo-1-methylpyrazole-3-carboxylic acid Chemical compound CN1N=C(C(O)=O)C=C1Br QLYDIHRYOAQXJT-UHFFFAOYSA-N 0.000 description 1
- XPERZSKJGNUSHI-UHFFFAOYSA-N 5-bromo-3-iodopyridin-2-amine Chemical compound NC1=NC=C(Br)C=C1I XPERZSKJGNUSHI-UHFFFAOYSA-N 0.000 description 1
- UQIXRPGOJAUMPE-UHFFFAOYSA-N 5-bromo-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]-1H-imidazole-2-carboxylic acid Chemical compound Cc1noc(n1)-c1cc2cc(ccc2[nH]1)-c1nc([nH]c1Br)C(O)=O UQIXRPGOJAUMPE-UHFFFAOYSA-N 0.000 description 1
- HRCIRIMJDZIYSN-UHFFFAOYSA-N 5-methyl-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]-1H-imidazole-2-carboxamide Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C2=C(NC(=N2)C(N)=O)C)=N1 HRCIRIMJDZIYSN-UHFFFAOYSA-N 0.000 description 1
- CMKWGMNMXRXSCJ-UHFFFAOYSA-N 5-methyl-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]-N-(2-morpholin-4-ylethyl)-1H-imidazole-2-carboxamide Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C2=C(NC(=N2)C(=O)NCCN2CCOCC2)C)=N1 CMKWGMNMXRXSCJ-UHFFFAOYSA-N 0.000 description 1
- BOCJJCQBJHJSJO-UHFFFAOYSA-N 5-methyl-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]-N-(oxan-2-ylmethyl)-1H-imidazole-2-carboxamide Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C2=C(NC(=N2)C(=O)NCC2OCCCC2)C)=N1 BOCJJCQBJHJSJO-UHFFFAOYSA-N 0.000 description 1
- OLVFVQFXLGGUJP-UHFFFAOYSA-N 5-methyl-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]-N-(oxan-4-yl)-1H-imidazole-2-carboxamide Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C2=C(NC(=N2)C(=O)NC2CCOCC2)C)=N1 OLVFVQFXLGGUJP-UHFFFAOYSA-N 0.000 description 1
- ACYHIBQTZOUDDX-UHFFFAOYSA-N 5-methyl-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]-N-(pyridin-4-ylmethyl)-1H-imidazole-2-carboxamide Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C2=C(NC(=N2)C(=O)NCC=2C=CN=CC=2)C)=N1 ACYHIBQTZOUDDX-UHFFFAOYSA-N 0.000 description 1
- GLHZGJCELNGIJL-UHFFFAOYSA-N 5-methyl-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]-N-[(6-oxo-1H-pyridin-3-yl)methyl]-1H-imidazole-2-carboxamide Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C2=C(NC(=N2)C(=O)NCC2=CNC(=O)C=C2)C)=N1 GLHZGJCELNGIJL-UHFFFAOYSA-N 0.000 description 1
- DUIODLDINBXUEC-UHFFFAOYSA-N 5-methyl-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]-N-[[4-(2,2,2-trifluoro-1-hydroxyethyl)phenyl]methyl]-1H-imidazole-2-carboxamide Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C2=C(NC(=N2)C(=O)NCC=2C=CC(=CC=2)C(O)C(F)(F)F)C)=N1 DUIODLDINBXUEC-UHFFFAOYSA-N 0.000 description 1
- IRCIJPFBTLMLDM-UHFFFAOYSA-N 5-methyl-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]pyridine-2-carboxylic acid Chemical compound Cc1noc(n1)-c1cc2cc(ccc2[nH]1)-c1cc(ncc1C)C(O)=O IRCIJPFBTLMLDM-UHFFFAOYSA-N 0.000 description 1
- QSVJHUOZXCBGDQ-UHFFFAOYSA-N 5-methyl-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]-N-(pyridin-4-ylmethyl)-1H-imidazole-2-carboxamide Chemical compound CC1=NOC(C=2NC3=CC=C(N=C3C=2)C2=C(NC(=N2)C(=O)NCC=2C=CN=CC=2)C)=N1 QSVJHUOZXCBGDQ-UHFFFAOYSA-N 0.000 description 1
- AFACOXGCVSXABU-UHFFFAOYSA-N 5-methyl-4-[2-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]-1H-imidazole-2-carboxylic acid Chemical compound CC(C)c1noc(n1)-c1cc2cc(ccc2[nH]1)-c1nc([nH]c1C)C(O)=O AFACOXGCVSXABU-UHFFFAOYSA-N 0.000 description 1
- PCNVKBBKROTUNS-UHFFFAOYSA-N 6-bromo-2-methyl-3-nitropyridine Chemical compound CC1=NC(Br)=CC=C1[N+]([O-])=O PCNVKBBKROTUNS-UHFFFAOYSA-N 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010060971 Astrocytoma malignant Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- MMJPVSDTLGFIQW-UHFFFAOYSA-N BI-4394 Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(N(N=1)C)=CC=1C(=O)NCC1=CC=C(C(O)=O)C=C1 MMJPVSDTLGFIQW-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- JLISOJIZGAIARE-UHFFFAOYSA-N CC1=C(C=CC(=C1)C2=CC3=C(N2C(=O)O)C=CC(=C3)Br)F Chemical compound CC1=C(C=CC(=C1)C2=CC3=C(N2C(=O)O)C=CC(=C3)Br)F JLISOJIZGAIARE-UHFFFAOYSA-N 0.000 description 1
- PIGKSWUDSOBXMG-UHFFFAOYSA-N CCOC(C(Cc1nc(Br)ccc1[N+](O)=O)=O)=O Chemical compound CCOC(C(Cc1nc(Br)ccc1[N+](O)=O)=O)=O PIGKSWUDSOBXMG-UHFFFAOYSA-N 0.000 description 1
- KAFGTBPOUZUBLP-UHFFFAOYSA-N CCOC(c([nH]c(c1c2)ccc2Br)c1F)=O Chemical compound CCOC(c([nH]c(c1c2)ccc2Br)c1F)=O KAFGTBPOUZUBLP-UHFFFAOYSA-N 0.000 description 1
- XHKMYKCHTBBRKY-UHFFFAOYSA-N CCOC(c1cc(nc(cc2)-c3c(C)[n](COCC[Si](C)(C)C4C=NC=CC(CNC5=O)=C4)c5n3)c2[n]1C(OC(C)(C)C)=O)=O Chemical compound CCOC(c1cc(nc(cc2)-c3c(C)[n](COCC[Si](C)(C)C4C=NC=CC(CNC5=O)=C4)c5n3)c2[n]1C(OC(C)(C)C)=O)=O XHKMYKCHTBBRKY-UHFFFAOYSA-N 0.000 description 1
- FPZAWMRPXSYJJB-UHFFFAOYSA-N CCOC(c1cc2cc(-c3cc(C(NCc(cc4)ccc4C(OC)=O)=O)n[n]3C)ccc2[nH]1)=O Chemical compound CCOC(c1cc2cc(-c3cc(C(NCc(cc4)ccc4C(OC)=O)=O)n[n]3C)ccc2[nH]1)=O FPZAWMRPXSYJJB-UHFFFAOYSA-N 0.000 description 1
- WUHUHIUGKBGHND-UHFFFAOYSA-N CCOC(c1cc2nc([Br]=C)ccc2[nH]1)=O Chemical compound CCOC(c1cc2nc([Br]=C)ccc2[nH]1)=O WUHUHIUGKBGHND-UHFFFAOYSA-N 0.000 description 1
- IWOKRTHKTAEDLP-UHFFFAOYSA-N COC(=O)C=1C=C(O)N(C)N=1 Chemical compound COC(=O)C=1C=C(O)N(C)N=1 IWOKRTHKTAEDLP-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PNIWWLCJFMKBOB-QRVIBDJDSA-N Cc([n](COCC[Si+](C)(C)C)c(C(NCc1ccc(/C=N\C)cc1)=O)n1)c1[Br]=C Chemical compound Cc([n](COCC[Si+](C)(C)C)c(C(NCc1ccc(/C=N\C)cc1)=O)n1)c1[Br]=C PNIWWLCJFMKBOB-QRVIBDJDSA-N 0.000 description 1
- SFNCQGJFYYHXOB-UHFFFAOYSA-N Cc1c(-c(cc2)nc3c2[nH]c(C(O)=O)c3)nc(C(NC2)=O)[n]1COCC[Si+](C)(C)C1C=NC=CC2=C1 Chemical compound Cc1c(-c(cc2)nc3c2[nH]c(C(O)=O)c3)nc(C(NC2)=O)[n]1COCC[Si+](C)(C)C1C=NC=CC2=C1 SFNCQGJFYYHXOB-UHFFFAOYSA-N 0.000 description 1
- MOOFMRGLIRJCRB-UHFFFAOYSA-N Cc1c(-c2ccc3[nH]c(-c4nc(C)n[o]4)cc3c2)nc(C(NCc(cc2)ccc2C#N)=O)[n]1COCC[Si+](C)(C)C Chemical compound Cc1c(-c2ccc3[nH]c(-c4nc(C)n[o]4)cc3c2)nc(C(NCc(cc2)ccc2C#N)=O)[n]1COCC[Si+](C)(C)C MOOFMRGLIRJCRB-UHFFFAOYSA-N 0.000 description 1
- PXQBIZBEKKARDD-UHFFFAOYSA-N Cc1c(-c2ccc3[nH]c(-c4nc(C)n[o]4)cc3c2)nc(CNCc(cc2)ccc2F)[nH]1 Chemical compound Cc1c(-c2ccc3[nH]c(-c4nc(C)n[o]4)cc3c2)nc(CNCc(cc2)ccc2F)[nH]1 PXQBIZBEKKARDD-UHFFFAOYSA-N 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 1
- 101000627854 Homo sapiens Matrix metalloproteinase-26 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- 208000000265 Lobular Carcinoma Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 101150014058 MMP1 gene Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
- 102100024128 Matrix metalloproteinase-26 Human genes 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 206010027761 Mixed hepatocellular cholangiocarcinoma Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- IEJLDQDLJZGGHB-UHFFFAOYSA-N N-(1,4-dioxan-2-ylmethyl)-5-methyl-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]-1H-imidazole-2-carboxamide Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C2=C(NC(=N2)C(=O)NCC2OCCOC2)C)=N1 IEJLDQDLJZGGHB-UHFFFAOYSA-N 0.000 description 1
- OPWZHRGHDVTLOM-UHFFFAOYSA-N N-[(2-aminopyridin-4-yl)methyl]-5-methyl-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]-1H-imidazole-2-carboxamide Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C2=C(N=C(N2)C(=O)NCC=2C=C(N)N=CC=2)C)=N1 OPWZHRGHDVTLOM-UHFFFAOYSA-N 0.000 description 1
- MHSBTTHKZMQJCP-UHFFFAOYSA-N N-[(4-cyanophenyl)methyl]-1-methyl-5-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]pyrazole-3-carboxamide Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C=2N(N=C(C=2)C(=O)NCC=2C=CC(=CC=2)C#N)C)=N1 MHSBTTHKZMQJCP-UHFFFAOYSA-N 0.000 description 1
- UCPAZUWZHAYDFX-UHFFFAOYSA-N N-[(4-cyanophenyl)methyl]-5-methyl-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]-1H-imidazole-2-carboxamide Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C2=C(NC(=N2)C(=O)NCC=2C=CC(=CC=2)C#N)C)=N1 UCPAZUWZHAYDFX-UHFFFAOYSA-N 0.000 description 1
- KHWHUMWPAFSJQZ-UHFFFAOYSA-N N-[(4-fluorophenyl)methyl]-1-methyl-5-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]pyrazole-3-carboxamide Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C=2N(N=C(C=2)C(=O)NCC=2C=CC(F)=CC=2)C)=N1 KHWHUMWPAFSJQZ-UHFFFAOYSA-N 0.000 description 1
- LKRJFDDGBREMMM-UHFFFAOYSA-N N-[(4-fluorophenyl)methyl]-5-methyl-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]-1H-imidazole-2-carboxamide Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C2=C(NC(=N2)C(=O)NCC=2C=CC(F)=CC=2)C)=N1 LKRJFDDGBREMMM-UHFFFAOYSA-N 0.000 description 1
- KJVGQOBRNXAXJR-UHFFFAOYSA-N N-[(4-hydroxyoxan-4-yl)methyl]-5-methyl-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]-1H-imidazole-2-carboxamide Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C2=C(NC(=N2)C(=O)NCC2(O)CCOCC2)C)=N1 KJVGQOBRNXAXJR-UHFFFAOYSA-N 0.000 description 1
- LTEKTKPVQLUBRW-UHFFFAOYSA-N N-[(6-aminopyridin-3-yl)methyl]-5-methyl-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]-1H-imidazole-2-carboxamide Chemical compound CC1=NOC(C=2NC3=CC=C(C=C3C=2)C2=C(N=C(N2)C(=O)NCC=2C=NC(N)=CC=2)C)=N1 LTEKTKPVQLUBRW-UHFFFAOYSA-N 0.000 description 1
- OJRKCEOPYYIQFG-UHFFFAOYSA-N N-ethyl-5-methyl-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]-1H-imidazole-2-carboxamide Chemical compound N1C(C(=O)NCC)=NC(C=2C=C3C=C(NC3=CC=2)C=2ON=C(C)N=2)=C1C OJRKCEOPYYIQFG-UHFFFAOYSA-N 0.000 description 1
- QIZVRAJZPGGXGJ-UHFFFAOYSA-N N-ethyl-5-methyl-4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(=O)NCC)=CC(C=2C=C3C=C(NC3=CC=2)C=2ON=C(C)N=2)=C1C QIZVRAJZPGGXGJ-UHFFFAOYSA-N 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
- 108030001564 Neutrophil collagenases Proteins 0.000 description 1
- 102000056189 Neutrophil collagenases Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 208000021161 Plasma cell disease Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- GCTFWCDSFPMHHS-UHFFFAOYSA-M Tributyltin chloride Chemical compound CCCC[Sn](Cl)(CCCC)CCCC GCTFWCDSFPMHHS-UHFFFAOYSA-M 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 description 1
- 102000036861 Zinc-dependent endopeptidases Human genes 0.000 description 1
- 108091006982 Zinc-dependent endopeptidases Proteins 0.000 description 1
- VVOPACXLTWJKRJ-UHFFFAOYSA-N [5-bromo-1-(tert-butylcarbamoyl)indol-2-yl]boronic acid Chemical compound BrC1=CC=C2N(C(=O)NC(C)(C)C)C(B(O)O)=CC2=C1 VVOPACXLTWJKRJ-UHFFFAOYSA-N 0.000 description 1
- FKCBLVCOSCZFHV-UHFFFAOYSA-N acetonitrile;ethanol Chemical compound CCO.CC#N FKCBLVCOSCZFHV-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 208000019664 bone resorption disease Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 201000007335 cerebellar astrocytoma Diseases 0.000 description 1
- 208000030239 cerebral astrocytoma Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 108700004333 collagenase 1 Proteins 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- RXFRHBVYVZYSJG-UHFFFAOYSA-N ethyl 3-(6-bromo-3-nitropyridin-2-yl)-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CC1=NC(Br)=CC=C1[N+]([O-])=O RXFRHBVYVZYSJG-UHFFFAOYSA-N 0.000 description 1
- CJGISVPPOUWZBB-UHFFFAOYSA-N ethyl 5-(4-carbamoylpyridin-2-yl)-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C1=CC(C(N)=O)=CC=N1 CJGISVPPOUWZBB-UHFFFAOYSA-N 0.000 description 1
- JKJVYCFDDYXLFV-UHFFFAOYSA-N ethyl 5-[2-(pyridin-4-ylmethylcarbamoyl)pyridin-4-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(C=1)=CC=NC=1C(=O)NCC1=CC=NC=C1 JKJVYCFDDYXLFV-UHFFFAOYSA-N 0.000 description 1
- XQXKLBVMMQZKSC-UHFFFAOYSA-N ethyl 5-[2-[(2,4-dimethoxyphenyl)methylcarbamoyl]pyridin-4-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(C=1)=CC=NC=1C(=O)NCC1=CC=C(OC)C=C1OC XQXKLBVMMQZKSC-UHFFFAOYSA-N 0.000 description 1
- UWNGLHPTCBJFGL-UHFFFAOYSA-N ethyl 5-[2-[(4-fluoro-3-methylphenyl)methylcarbamoyl]pyridin-4-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(C=1)=CC=NC=1C(=O)NCC1=CC=C(F)C(C)=C1 UWNGLHPTCBJFGL-UHFFFAOYSA-N 0.000 description 1
- JROBGTKVZUXNMF-UHFFFAOYSA-N ethyl 5-[2-[(4-phenylmethoxycarbonylphenyl)methylcarbamoyl]pyridin-4-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(C=1)=CC=NC=1C(=O)NCC(C=C1)=CC=C1C(=O)OCC1=CC=CC=C1 JROBGTKVZUXNMF-UHFFFAOYSA-N 0.000 description 1
- ATHJZADWADIPIE-UHFFFAOYSA-N ethyl 5-[2-[(6-oxo-1h-pyridin-3-yl)methylcarbamoyl]pyridin-4-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(C=1)=CC=NC=1C(=O)NCC=1C=CC(=O)NC=1 ATHJZADWADIPIE-UHFFFAOYSA-N 0.000 description 1
- XYAPTVNWZXNGOT-UHFFFAOYSA-N ethyl 5-[2-methyl-5-(pyridin-4-ylmethylcarbamoyl)pyrazol-3-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(N(N=1)C)=CC=1C(=O)NCC1=CC=NC=C1 XYAPTVNWZXNGOT-UHFFFAOYSA-N 0.000 description 1
- REANBRVQFZEMPZ-UHFFFAOYSA-N ethyl 5-[2-methyl-5-[(6-oxo-1h-pyridin-3-yl)methylcarbamoyl]pyrazol-3-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(N(N=1)C)=CC=1C(=O)NCC=1C=CC(=O)NC=1 REANBRVQFZEMPZ-UHFFFAOYSA-N 0.000 description 1
- RTVYZXHYYKEKLF-UHFFFAOYSA-N ethyl 5-[3-(1,3-benzodioxol-5-ylmethylcarbamoyl)phenyl]-1h-indole-2-carboxylate Chemical compound C1=C2OCOC2=CC(CNC(=O)C=2C=CC=C(C=2)C=2C=C3C=C(NC3=CC=2)C(=O)OCC)=C1 RTVYZXHYYKEKLF-UHFFFAOYSA-N 0.000 description 1
- OPSPFKGCZPKZJK-UHFFFAOYSA-N ethyl 5-[4-[(2,4-dimethoxyphenyl)methylcarbamoyl]pyrimidin-2-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(N=1)=NC=CC=1C(=O)NCC1=CC=C(OC)C=C1OC OPSPFKGCZPKZJK-UHFFFAOYSA-N 0.000 description 1
- MRCCOHLECPGIQU-UHFFFAOYSA-N ethyl 5-[4-methyl-5-(pyridin-4-ylmethylcarbamoyl)thiophen-3-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(C=1C)=CSC=1C(=O)NCC1=CC=NC=C1 MRCCOHLECPGIQU-UHFFFAOYSA-N 0.000 description 1
- QOMUVAJBDRFCDK-UHFFFAOYSA-N ethyl 5-[5-(pyridin-4-ylmethylcarbamoyl)pyridin-3-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(C=1)=CN=CC=1C(=O)NCC1=CC=NC=C1 QOMUVAJBDRFCDK-UHFFFAOYSA-N 0.000 description 1
- QSECAXNAQDYGBF-UHFFFAOYSA-N ethyl 5-[5-(pyridin-4-ylmethylcarbamoyl)thiophen-3-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(C=1)=CSC=1C(=O)NCC1=CC=NC=C1 QSECAXNAQDYGBF-UHFFFAOYSA-N 0.000 description 1
- ICNAIBAXEDVMED-UHFFFAOYSA-N ethyl 5-[5-[(2,4-dimethoxyphenyl)methylcarbamoyl]pyridin-3-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(C=1)=CN=CC=1C(=O)NCC1=CC=C(OC)C=C1OC ICNAIBAXEDVMED-UHFFFAOYSA-N 0.000 description 1
- RPHUWDYIPYHJHR-UHFFFAOYSA-N ethyl 5-[5-[(2,4-dimethoxyphenyl)methylcarbamoyl]thiophen-3-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(C=1)=CSC=1C(=O)NCC1=CC=C(OC)C=C1OC RPHUWDYIPYHJHR-UHFFFAOYSA-N 0.000 description 1
- XWKYBZNOWOCQDY-UHFFFAOYSA-N ethyl 5-[5-[(4-fluoro-3-methylphenyl)methylcarbamoyl]-4-methylthiophen-3-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(C=1C)=CSC=1C(=O)NCC1=CC=C(F)C(C)=C1 XWKYBZNOWOCQDY-UHFFFAOYSA-N 0.000 description 1
- BLQQJDCUFAYMAA-UHFFFAOYSA-N ethyl 5-[5-[(4-fluoro-3-methylphenyl)methylcarbamoyl]pyridin-3-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(C=1)=CN=CC=1C(=O)NCC1=CC=C(F)C(C)=C1 BLQQJDCUFAYMAA-UHFFFAOYSA-N 0.000 description 1
- DKPMYLVBZVZUKV-UHFFFAOYSA-N ethyl 5-[5-[(4-fluoro-3-methylphenyl)methylcarbamoyl]thiophen-3-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(C=1)=CSC=1C(=O)NCC1=CC=C(F)C(C)=C1 DKPMYLVBZVZUKV-UHFFFAOYSA-N 0.000 description 1
- HEKKTBLJJPWUTF-UHFFFAOYSA-N ethyl 5-[5-[[4-(2-methoxy-2-oxoethyl)phenyl]methylcarbamoyl]-2-methylpyrazol-3-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(N(N=1)C)=CC=1C(=O)NCC1=CC=C(CC(=O)OC)C=C1 HEKKTBLJJPWUTF-UHFFFAOYSA-N 0.000 description 1
- HSXLXHWBXOXGIU-UHFFFAOYSA-N ethyl 5-[5-methyl-2-(pyridin-4-ylmethylcarbamoyl)-1-(2-trimethylsilylethoxymethyl)imidazol-4-yl]-1h-pyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound C=1N=C2NC(C(=O)OCC)=CC2=CC=1C(=C(N1COCC[Si](C)(C)C)C)N=C1C(=O)NCC1=CC=NC=C1 HSXLXHWBXOXGIU-UHFFFAOYSA-N 0.000 description 1
- LOYMWGWTHCOYLD-UHFFFAOYSA-N ethyl 5-[5-methyl-2-(pyridin-4-ylmethylcarbamoyl)-1h-imidazol-4-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(=C(N=1)C)NC=1C(=O)NCC1=CC=NC=C1 LOYMWGWTHCOYLD-UHFFFAOYSA-N 0.000 description 1
- BKDVYJPTBFRCIR-UHFFFAOYSA-N ethyl 5-[5-methyl-2-(pyridin-4-ylmethylcarbamoyl)-1h-imidazol-4-yl]-1h-pyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound C=1N=C2NC(C(=O)OCC)=CC2=CC=1C(=C(N=1)C)NC=1C(=O)NCC1=CC=NC=C1 BKDVYJPTBFRCIR-UHFFFAOYSA-N 0.000 description 1
- FNZCCNYXWBUTMG-UHFFFAOYSA-N ethyl 5-[5-methyl-2-(pyridin-4-ylmethylcarbamoyl)-1h-imidazol-4-yl]-1h-pyrrolo[2,3-c]pyridine-2-carboxylate Chemical compound N=1C=C2NC(C(=O)OCC)=CC2=CC=1C(=C(N1)C)N=C1C(=O)NCC1=CC=NC=C1 FNZCCNYXWBUTMG-UHFFFAOYSA-N 0.000 description 1
- DMKUTALHEIQGEX-UHFFFAOYSA-N ethyl 5-[5-methyl-2-(pyridin-4-ylmethylcarbamoyl)pyridin-4-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(C(=CN=1)C)=CC=1C(=O)NCC1=CC=NC=C1 DMKUTALHEIQGEX-UHFFFAOYSA-N 0.000 description 1
- CZKFKQNTRLGEHJ-UHFFFAOYSA-N ethyl 5-[6-[(2,4-dimethoxyphenyl)methylcarbamoyl]pyridin-2-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(N=1)=CC=CC=1C(=O)NCC1=CC=C(OC)C=C1OC CZKFKQNTRLGEHJ-UHFFFAOYSA-N 0.000 description 1
- HSKSMPLWLZVDQM-UHFFFAOYSA-N ethyl 5-[6-[(4-fluoro-3-methylphenyl)methylcarbamoyl]pyridin-2-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(N=1)=CC=CC=1C(=O)NCC1=CC=C(F)C(C)=C1 HSKSMPLWLZVDQM-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- FQYYIPZPELSLDK-UHFFFAOYSA-N ethyl pyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=CC=N1 FQYYIPZPELSLDK-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 210000001752 female genitalia Anatomy 0.000 description 1
- 102000013373 fibrillar collagen Human genes 0.000 description 1
- 108060002894 fibrillar collagen Proteins 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 1
- 201000008893 intraocular retinoblastoma Diseases 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000030883 malignant astrocytoma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
- 208000025848 malignant tumor of nasopharynx Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- FBGBHZFPHQHNRA-UHFFFAOYSA-N methyl 1-methyl-5-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-indol-5-yl]pyrazole-3-carboxylate Chemical compound C1(C2=CC=3C=C(C=4ON=C(N=4)C)NC=3C=C2)=CC(C(=O)OC)=NN1C FBGBHZFPHQHNRA-UHFFFAOYSA-N 0.000 description 1
- AQBJGAUQEJFPKZ-UHFFFAOYSA-N methyl 4-(aminomethyl)benzoate Chemical compound COC(=O)C1=CC=C(CN)C=C1 AQBJGAUQEJFPKZ-UHFFFAOYSA-N 0.000 description 1
- CHZMHMZDGFLWEQ-UHFFFAOYSA-N methyl 4-[[(5-bromo-1-methylpyrazole-3-carbonyl)amino]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CNC(=O)C1=NN(C)C(Br)=C1 CHZMHMZDGFLWEQ-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- AEXITZJSLGALNH-UHFFFAOYSA-N n'-hydroxyethanimidamide Chemical compound CC(N)=NO AEXITZJSLGALNH-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- AFPRSRCSTLVQCY-UHFFFAOYSA-N n-(2-hydroxyethyl)-5-[2-(pyridin-4-ylmethylcarbamoyl)pyridin-4-yl]-1h-indole-2-carboxamide Chemical compound C=1C=C2NC(C(=O)NCCO)=CC2=CC=1C(C=1)=CC=NC=1C(=O)NCC1=CC=NC=C1 AFPRSRCSTLVQCY-UHFFFAOYSA-N 0.000 description 1
- DCNYZECJIWXIJP-UHFFFAOYSA-N n-ethyl-5-[2-(pyridin-4-ylmethylcarbamoyl)pyridin-4-yl]-1h-indole-2-carboxamide Chemical compound C=1C=C2NC(C(=O)NCC)=CC2=CC=1C(C=1)=CC=NC=1C(=O)NCC1=CC=NC=C1 DCNYZECJIWXIJP-UHFFFAOYSA-N 0.000 description 1
- DIZOMGFKSMFDOO-UHFFFAOYSA-N n-methoxy-5-[2-(pyridin-4-ylmethylcarbamoyl)pyridin-4-yl]-1h-indole-2-carboxamide Chemical compound C=1C=C2NC(C(=O)NOC)=CC2=CC=1C(C=1)=CC=NC=1C(=O)NCC1=CC=NC=C1 DIZOMGFKSMFDOO-UHFFFAOYSA-N 0.000 description 1
- GUSAIXRLXFUFJI-UHFFFAOYSA-N n-methoxy-n-methyl-5-[2-(pyridin-4-ylmethylcarbamoyl)pyridin-4-yl]-1h-indole-2-carboxamide Chemical compound C=1C=C2NC(C(=O)N(C)OC)=CC2=CC=1C(C=1)=CC=NC=1C(=O)NCC1=CC=NC=C1 GUSAIXRLXFUFJI-UHFFFAOYSA-N 0.000 description 1
- LSCYTCMNCWMCQE-UHFFFAOYSA-N n-methylpyridin-4-amine Chemical compound CNC1=CC=NC=C1 LSCYTCMNCWMCQE-UHFFFAOYSA-N 0.000 description 1
- OCFBMPLLSMDFHL-UHFFFAOYSA-N n-pyridin-4-yl-5-[2-(pyridin-4-ylmethylcarbamoyl)pyridin-4-yl]-1h-indole-2-carboxamide Chemical compound C=1C2=CC(C=3C=C(N=CC=3)C(=O)NCC=3C=CN=CC=3)=CC=C2NC=1C(=O)NC1=CC=NC=C1 OCFBMPLLSMDFHL-UHFFFAOYSA-N 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 208000023833 nerve sheath neoplasm Diseases 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- WBSKWRZGNHBHNQ-UHFFFAOYSA-N tert-butyl 5-[2-(pyridin-4-ylmethylcarbamoyl)pyridin-4-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OC(C)(C)C)=CC2=CC=1C(C=1)=CC=NC=1C(=O)NCC1=CC=NC=C1 WBSKWRZGNHBHNQ-UHFFFAOYSA-N 0.000 description 1
- OWPIFQXNMLDXKW-UHFFFAOYSA-N tert-butyl indole-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OC(C)(C)C)C=CC2=C1 OWPIFQXNMLDXKW-UHFFFAOYSA-N 0.000 description 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- PWLROCHXTREGKR-UHFFFAOYSA-N trimethyl-[2-[(2,4,5-tribromoimidazol-1-yl)methoxy]ethyl]silane Chemical compound C[Si](C)(C)CCOCN1C(Br)=NC(Br)=C1Br PWLROCHXTREGKR-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Description
この出願は、2008年10月17日に出願された米国仮出願番号第61/106,207号の利益を請求する。
1.技術分野
本発明は、MMP−13メタロプロテアーゼ阻害化合物に関する。
マトリックスメタロプロテイナーゼ(MMP)は、亜鉛依存性エンドペプチダーゼである。MMPは、細胞外基質タンパク質を分解するように機能し、細胞表面受容体、成長因子、細胞接着分子、サイトカイン及びケモカイン、ならびに他のMMP及び関連していないプロテアーゼの開裂に関与する。MMPはまた、増殖、移動(接着/分散)、分化、血管形成、アポトーシス及び宿主防衛などの細胞プロセスに対して主要な役割を果たすと考えられている。(Hu J. et al. Nat. Rev. Drug Discov. 2007, 6:480-498; Ramnath N. and Creaven P. J. Curr. Onco. Rep. 2004, 6:96-102)。したがって、MMPは、関節リウマチ、変形性関節症、骨粗鬆症、歯周炎、アテローム性動脈硬化、鬱血性心不全、多発性硬化症及び腫瘍転移を含む治療疾患の標的である。
本発明の化合物がMMP−13の阻害剤であることが見出された。
最も広範な一般的実施態様において、式(I):
[式中、
Hetは、フェニル、ヘテロアリール及びヘテロサイクル(それぞれ、1〜3個のC1−5アルキル、C1−5アルコキシ、C1−5アシル、C1−5アシルアミノ、アミノ、シアノ、ヒドロキシル又はハロゲンにより場合により置換されている)より選択される環であり;
Xは、−O−又は−N(R3)−であり;
Yは、N又はCであり、
Zは、H又はFであり、
R1は、C1−5アルキル、C1−5アルコキシC1−5アルキル、C1−5アルコキシ、C1−5アルコキシカルボニル−(CH2)n−、HOC(=O)−(CH2)n−、ヒドロキシC1−5アルキル、−C(O)NR4R5及びAr1より選択され;
R2は、水素、Ar2−(CH2)n−、ヘテロサイクル、又はC1−5アルキルより選択され;
R3は、水素及びC1−5アルキルより選択され;
各R4及びR5は、独立して、水素、C1−5アシル、C1−5アルキル、C1−5アルコキシ、ヒドロキシル、カルボサイクル−(CH2)n−、ヘテロアリール−(CH2)n−及びヘテロサイクル−(CH2)n−より選択され;
Ar1は、カルボサイクル、ヘテロアリール及びヘテロサイクル(ここで、Ar1は、1〜3個のC1−5アルキル、C1−5アルコキシ、C1−5アシル、C1−5アシルアミノ、アミノ、シアノ、ヒドロキシル又はハロゲンにより場合により置換されている)より選択され;
Ar2は、カルボサイクル、ヘテロアリール及びヘテロサイクル(ここで、Ar2は、1〜3個のヘテロアリール、C1−5アルキル、C1−5アルコキシ−(CH2)n−、C1−5アルコキシカルボニル−(CH2)n−、カルボキシ−(CH2)n−、C1−5アシル、C1−5アシルアミノ、アミノ、シアノ、ヒドロキシル、スルホニル、スルホキシド、チオ、オキソ又はハロゲンにより場合により置換されている)より選択され;
各nは、独立して、0〜2である]で示される化合物、又はその薬学的に許容しうる塩が提供される。
[式中、
Xは、−N(R3)−であり;
Hetは、オキサゾリル、イソオキサゾリル、オキサジアゾリル、チアゾリル、イソチアゾリル、ピラゾリル、ピロリル、イミダゾリル、ピリジニル、ピリミジニル、ピリダジニル及びピラジニル(それぞれ、1〜3個のC1−5アルキル、C1−5アルコキシ、C1−5アシル、C1−5アシルアミノ、アミノ、シアノ、ヒドロキシル又はハロゲンにより場合により置換されている)より選択される環であり;
R1は、C1−5アルコキシC1−5アルキル、C1−5アルコキシカルボニル−(CH2)n−及びAr1より選択され;
R2は、Ar2−(CH2)n−、ヘテロサイクル、又はC1−5アルキルより選択され;
Ar1は、フェニル、オキサゾリル、4,5−ジヒドロ−オキサゾリル、イソオキサゾリル、オキサジアゾリル、チアゾリル、ピラゾリル、ピロリル、イミダゾリル、ピリジニル、ピリミジニル、ピリダジニル及びピラジニル(ここで、Ar1は、1〜3個のC1−5アルキル、C1−5アルコキシ、C1−5アシル、C1−5アシルアミノ、アミノ、シアノ、ヒドロキシル又はハロゲンにより場合により置換されている)より選択され;
Ar2は、フェニル、オキサゾリル、イソオキサゾリル、オキサジアゾリル、フラニル、チオフェニル、トリアゾリル、チアジアゾリル、イソチアゾリル、チアゾリル、ピラゾリル、ピロリル、イミダゾリル、ピリジニル、ピリミジニル、ピリダジニル及びピラジニル(ここで、Ar2は、1〜3個のC1−5アルキル、C1−5アルコキシ−(CH2)n−、C1−5アルコキシカルボニル−(CH2)n−、カルボキシ−(CH2)n−、C1−5アシル、C1−5アシルアミノ、アミノ、シアノ、ヒドロキシル、オキソ又はハロゲンにより場合により置換されている)より選択される]で示される化合物、又はその薬学的に許容しうる塩が提供される。
[式中、
Hetは、フェニル、ヘテロアリール及びヘテロサイクル(それぞれ、1〜3個のC1−5アルキル、C1−5アルコキシ、C1−5アシル、C1−5アシルアミノ、アミノ、シアノ、ヒドロキシル又はハロゲンにより場合により置換されている)より選択される環であり;
Xは、−O−又は−N(R3)−であり;
R1は、C1−5アルキル、C1−5アルコキシC1−5アルキル、C1−5アルコキシ、C1−5アルコキシカルボニル−(CH2)n−、HOC(=O)−(CH2)n−、ヒドロキシC1−5アルキル、−C(O)NR4R5及びAr1より選択され;
R2は、水素、Ar2−(CH2)n−ヘテロサイクル、又はC1−5アルキルより選択され;
R3は、水素及びC1−5アルキルより選択され;
各R4及びR5は、独立して、水素、C1−5アシル、C1−5アルキル、C1−5アルコキシ、ヒドロキシル、カルボサイクル−(CH2)n−、ヘテロアリール−(CH2)n−及びヘテロサイクル−(CH2)n−より選択され;
Ar1は、カルボサイクル、ヘテロアリール及びヘテロサイクル(ここで、Ar1は、1〜3個のC1−5アルキル、C1−5アルコキシ、C1−5アシル、C1−5アシルアミノ、アミノ、シアノ、ヒドロキシル又はハロゲンにより場合により置換されている)より選択され;
Ar2は、カルボサイクル、ヘテロアリール及びヘテロサイクル(ここで、Ar2は、1〜3個のヘテロアリール、C1−5アルキル、C1−5アルコキシ−(CH2)n−、C1−5アルコキシカルボニル−(CH2)n−、カルボキシ−(CH2)n−、C1−5アシル、C1−5アシルアミノ、アミノ、シアノ、ヒドロキシル、スルホニル、スルホキシド、チオ、オキソ又はハロゲンにより場合により置換されている)より選択され;
各nは、独立して、0〜2である]で示される化合物が提供される。
[式中、
Xは、−N(R3)−であり;
Hetは、オキサゾリル、イソオキサゾリル、オキサジアゾリル、チアゾリル、イソチアゾリル、ピラゾリル、ピロリル、イミダゾリル、ピリジニル、ピリミジニル、ピリダジニル及びピラジニル(それぞれ、1〜3個のC1−5アルキル、C1−5アルコキシ、C1−5アシル、C1−5アシルアミノ、アミノ、シアノ、ヒドロキシル又はハロゲンにより場合により置換されている)より選択される環であり;
R1は、C1−5アルコキシC1−5アルキル、C1−5アルコキシカルボニル−(CH2)n−及びAr1より選択され;
R2は、Ar2−(CH2)n−より選択され;
Ar1は、フェニル、オキサゾリル、4,5−ジヒドロ−オキサゾリル、イソオキサゾリル、オキサジアゾリル、チアゾリル、ピラゾリル、ピロリル、イミダゾリル、ピリジニル、ピリミジニル、ピリダジニル及びピラジニル(ここで、Ar1は、1〜3個のC1−5アルキル、C1−5アルコキシ、C1−5アシル、C1−5アシルアミノ、アミノ、シアノ、ヒドロキシル又はハロゲンにより場合により置換されている)より選択され;
Ar2は、フェニル、オキサゾリル、イソオキサゾリル、オキサジアゾリル、チアゾリル、ピラゾリル、ピロリル、イミダゾリル、ピリジニル、ピリミジニル、ピリダジニル及びピラジニル(ここで、Ar2は、1〜3個のC1−5アルキル、C1−5アルコキシ−(CH2)n−、C1−5アルコキシカルボニル−(CH2)n−、カルボキシ−(CH2)n−、C1−5アシル、C1−5アシルアミノ、アミノ、シアノ、ヒドロキシル、オキソ又はハロゲンにより場合により置換されている)より選択される]で示される化合物が提供される。
[式中、
Hetは、ピラゾリル、イミダゾリル及びピリジニル(それぞれ、1〜3個のC1−5アルキル、C1−5アルコキシ、C1−5アシル、C1−5アシルアミノ、アミノ、シアノ、ヒドロキシル又はハロゲンにより場合により置換されている)より選択される環であり;
Ar1は、フェニル、オキサゾリル、4,5−ジヒドロ−オキサゾリル、イソオキサゾリル、オキサジアゾリル、ピラゾリル、イミダゾリル、ピリジニル及びピリミジニル(ここで、Ar1は、1〜2個のC1−5アルキル又はハロゲンにより場合により置換されている)より選択され;
Ar2は、フェニル、ピリジニル、ピリミジニル、ピリダジニル及びピラジニル(ここで、Ar2は、1〜3個のC1−5アルキル、C1−5アルコキシ、C1−5アルコキシカルボニル、カルボキシ、又はハロゲンにより場合により置換されている)より選択される]で示される化合物が提供される。
[式中、
Hetは、ピラゾリル、イミダゾリル及びピリジニル(それぞれ、C1−5アルキル、C1−5アルコキシ又はハロゲンにより場合により置換されている)より選択される環であり;
R1は、C1−2アルコキシC1−2アルキル、C1−2アルコキシカルボニル及びAr1より選択され;
R2は、Ar2−CH2−より選択され;
Ar1は、フェニル、4,5−ジヒドロ−オキサゾリル、オキサジアゾリル、ピラゾリル、ピリジニル及びピリミジニル(ここで、Ar1は、1〜2個のC1−3アルキル又はハロゲンにより場合により置換されている)より選択され;
Ar2は、フェニル及びピリジニル(ここで、Ar2は、1〜2個のC1−5アルキル、C1−5アルコキシ、C1−5アルコキシカルボニル、ヒドロキシル、オキソ、カルボキシ、又はハロゲンにより場合により置換されている)より選択される]で示される化合物が提供される。
[式中、
Hetは、
[式中、
R2は、水素又はC1−4アルキルであり;
R1は、C1−5アルコキシC1−5アルキル、C1−5アルコキシカルボニル−及び
[式中、
Xは、−O−であり;
R1は、C1−5アルコキシカルボニル−である]で示される化合物が提供される。
本発明はまた、式(I)の化合物の製造方法を提供する。全てのスキームにおいて、他に示さない限り、下記の式中のR1、R2、X及び「Het」は、本明細書で上述の発明の式(I)中のR1、R2、X及び「Het」の意味を有するものとし、全てのスキームにおいて、式(I)についての合成は、等しく式(II)に適用される。
5−[5−(4−メトキシカルボニルメチル−ベンジルカルバモイル)−2−メチル−2H−ピラゾール−3−イル]−1H−インドール−2−カルボン酸エチルエステル
実施例1と同様にして合成した。17mg、11%、LC/MS ESI m/z (M+H)+=403.5。
実施例1と同様にして合成した。9mg、47%、LC/MS ESI m/z (M+H)+=420.3。
実施例1と同様にして合成した。22mg、10.7%、LC/MS ESI m/z (M+H)+=461.3。
実施例1と同様にして合成した。13mg、52%、LC/MS ESI m/z 446.5 (M+H)+=447.3。
実施例1と同様にして合成した。5mg、12%、LC/MS ESI m/z 444.1 (M+H)+=444.4。
実施例1と同様にして合成した。22mg、5%、LC/MS ESI m/z 419.6 418.4 (M+H)+=419.3。
実施例1と同様にして合成した。33mg、14% LC/MS ESI m/z (M+H)+=405.9。
実施例1と同様にして合成した。13mg、31% LC/MS ESI m/z (M+H)+=433.6。
実施例1と同様にして合成した。9mg、18% LC/MS ESI m/z (M+H)+=375.3。
実施例1と同様にして合成した。7mg 6% LC/MS ESI m/z (M+H)+=400.2。
実施例12と同様にして合成した。12mg、29% LC/MS ESI m/z (M+H)+=484.6。
実施例12と同様にして合成した。24mg、26%収率 LC/MS ESI m/z (M+H)+=470.4。
実施例12と同様にして合成した。10mg、22.1% LC/MS ESI m/z (M+H)+=453.4。
実施例12と同様にして合成した。8mg、9%収率 LC/MS ESI m/z (M+H)+=470.6。
実施例12と同様にして合成した。6mg、18%収率 LC/MS ESI m/z (M+H)+=455.4。
実施例12と同様にして合成した。10mg、45% LC/MS ESI m/z (M+H)+=453.4。
実施例12と同様にして合成した。20mg、29%収率 LC/MS ESI m/z (M+H)+=451.5。
実施例12と同様にして合成した。25mg、28%収率 LC/MS ESI m/z (M+H)+=452.4。
実施例22と同様にして合成した。25mg、23%、LC/MS ESI m/z (M+H)+=458.3。
実施例22と同様にして合成した。15mg、15% LC/MS ESI m/z (M+H)+=438.7。
実施例22と同様にして合成した。7mg、8% LC/MS ESI m/z (M+H)+=431.36.
実施例26と同様にして合成した。1.0g、96% LC/MS ESI m/z (M+H)+=351.9。
実施例26と同様にして合成した。15mg、35% LC/MS ESI m/z (M+H)+=430.3。
実施例29と同様にして合成した。23mg、61% LC/MS ESI m/z (M+H)+=457.7。
実施例30と同様にして合成した。5.0mg、3.3% LC/MS ESI m/z (M+H)+=404.1。
実施例30と同様にして合成した。8.0mg、49% LC/MS ESI m/z (M+H)+=432.2。
実施例30と同様にして合成した。20mg、13%、LC/MS ESI m/z (M+H)+=362.4。
実施例30と同様にして合成した。11mg、12%、LC/MS ESI m/z (M+H)+=425.4。
実施例30と同様にして合成した。12mg、24%、LC/MS ESI m/z (M+H)+=468.5。
実施例30と同様にして合成した。22mg、22%、LC/MS ESI m/z (M+H)+=310.1
実施例30と同様にして合成した。50mg、77%、LC/MS ESI m/z (M+H)+=401.3。
エタノール(4ml)中の5−{2−[(ピリジン−4−イルメチル)−カルバモイル]−ピリジン−4−イル}−1H−インドール−2−カルボン酸エチルエステル(160mg、0.4mmol)に、水酸化ナトリウム水溶液(2N)を加え、混合物を70℃で2時間撹拌した。反応物を冷却し、水(30ml)で希釈し、HCl水溶液(3N)でpH4〜5に酸性化し、ジクロロメタン(50ml)で抽出した。合わせた有機層を乾燥させ(硫酸ナトリウム)、濾過し、真空下で蒸発させて、標記化合物を得た。95mg、64%、LC/MS ESI m/z (M+H)+=273.8。
N,Nジメチルホルムアミド(1ml)中の5−{2−[(ピリジン−4−イルメチル)−カルバモイル]−ピリジン−4−イル}−1H−インドール−2−カルボン酸(40mg、0.1mmol)の混合物に、HATU(49mg、0.13mmol)、続いてN,N−ジイソプロピルエチルアミン(0.025ml、0.12mmol)を加えた。反応物を1/2時間撹拌した。エチルアミン(64μL、0.13mmol)を加え、反応混合物を24時間撹拌した。反応混合物を酢酸エチルで希釈し、水(3×)、炭酸ナトリウム(1×)、及びブライン(1×)で洗浄した。有機層をNa2SO4で乾燥させ、濾過し、真空下で蒸発させた。粗生成物を、逆相HPLCにより精製して、標記化合物を得た。8mg、19%、LC/MS ESI m/z (M+H)+=400.4。
実施例30と同様にして合成した。17mg、63% LC/MS ESI m/z (M+H)+=402.4。
実施例30と同様にして合成した。45mg、44% LC/MS ESI m/z (M+H)+=416.4。
実施例30と同様にして合成した。20mg、47% LC/MS ESI m/z (M+H)+=416.2。
実施例30と同様にして合成した。10mg、22% LC/MS ESI m/z (M+H)+=429.4。
実施例30と同様にして合成した。10mg、21% LC/MS ESI m/z (M+H)+=449.3。
実施例30と同様にして合成した。28mg、43% LC/MS ESI m/z (M+H)+=401.4。
実施例30と同様にして合成した。40mg、46% LC/MS ESI m/z (M+H)+=405.6。
実施例30と同様にして合成した。15mg、47% LC/MS ESI m/z (M+H)+=406.4。
実施例30と同様にして合成した。30mg、36% LC/MS ESI m/z (M+H)+=406.4。
実施例30と同様にして合成した。10mg、31% LC/MS ESI m/z (M+H)+=411.1。
実施例30と同様にして合成した。15mg、22% LC/MS ESI m/z (M+H)+=417.4。
実施例30と同様にして合成した。30mg、82% LC/MS ESI m/z (M+H)+=420.4。
実施例30と同様にして合成した。15mg、14% LC/MS ESI m/z (M+H)+=432.2。
実施例30と同様にして合成した。26mg、25% LC/MS ESI m/z (M+H)+=432.4。
実施例30と同様にして合成した。22mg、21% LC/MS ESI m/z (M+H)+=432.2。
実施例30と同様にして合成した。20mg、29% LC/MS ESI m/z (M+H)+=433.3。
実施例30と同様にして合成した。40mg、41% LC/MS ESI m/z (M+H)+=437.4。
実施例30と同様にして合成した。45mg、25% LC/MS ESI m/z (M+H)+=443.1。
実施例30と同様にして合成した。100mg、83% LC/MS ESI m/z (M+H)+=451.2。
実施例30と同様にして合成した。12mg、62% LC/MS ESI m/z (M+H)+=460.2。
実施例30と同様にして合成した。50mg、45% LC/MS ESI m/z (M+H)+=460.2。
実施例30と同様にして合成した。31mg、28% LC/MS ESI m/z (M+H)+=460.4。
実施例30と同様にして合成した。20mg、18% LC/MS ESI m/z (M+H)+=460.2。
実施例30と同様にして合成した。36mg、49% LC/MS ESI m/z (M+H)+=461.3。
実施例30と同様にして合成した。22mg、21% LC/MS ESI m/z (M+H)+=465.2。
実施例30と同様にして合成した。20mg、15% LC/MS ESI m/z (M+H)+=479.4。
実施例30と同様にして合成した。62mg、31% LC/MS ESI m/z (M+H)+=534.4。
5−[2−(4−ベンジルオキシカルボニル−ベンジルカルバモイル)−ピリジン−4−イル]−1H−インドール−2−カルボン酸エチルエステルから製造した。42mg、97%、LC/MS ESI m/z (M+H)+=444.4。
実施例30と同様にして合成した。7mg、6% LC/MS ESI m/z (M+H)+=511.4。
実施例30と同様にして合成した。5mg、5% LC/MS ESI m/z (M+H)+=414.9。
実施例30と同様にして合成した。5mg、5% LC/MS ESI m/z (M+H)+=423.3。
実施例30と同様にして合成した。3mg、3% LC/MS ESI m/z (M+H)+=415.0。
実施例26と同様にして合成した。8mg、12% LC/MS ESI m/z (M+H)+=436.52.
実施例26と同様にして合成した。14mg、23% LC/MS ESI m/z (M+H)+394.47.
実施例26と同様にして合成した。18mg、19% LC/MS ESI m/z (M+H)+421.52.
実施例26と同様にして合成した。14mg、21% LC/MS ESI m/z (M+H)+=437.49.
実施例26と同様にして合成した。4mg、6% LC/MS ESI m/z (M+H)+=407.51.
実施例26と同様にして合成した。28mg、37%、LC/MS ESI m/z (M+H)+=429.43。
実施例26と同様にして合成した。51mg、54%、LC/MS ESI m/z (M+H)+=429.43。
実施例70と同様にして合成した。20mg、10%、LC/MS ESI m/z (M+H)+=442.5。
式Iの化合物の生物学的特性は、他の技術分野で認められているアッセイに加え、下記のアッセイを使用して評価することができる。
上記アッセイにより示すことができるように、本発明の化合物は、MMP−13を阻害するのに有用である。したがって、本発明の化合物は、関節リウマチ、変形性関節症、骨粗鬆症、歯周炎、アテローム性動脈硬化症、鬱血性心不全、多発性硬化症及び腫瘍転移などの疾患の処置に有用である。それらは、薬剤として、特に本明細書に記載された医薬組成物の形態で患者に使用することできる。前述のように、MMP−13は、細胞外基質分解及び細胞プロセス、例えば、増殖、移動(凝集/分散)、分化、血管形成、アポトーシス及び宿主防御に対して主要な役割を果たすと考えられており、したがって、本発明の化合物はまた、以下の疾患の処置にも有用である:
接触性皮膚炎、骨吸収疾患、再灌流障害、喘息、ギラン−バレー症候群、クローン病、潰瘍性大腸炎、乾癬、移植片対宿主疾患、全身性エリテマトーデス及びインスリン依存性糖尿病、毒素性ショック症候群、アルツハイマー病、糖尿病、炎症性腸疾患、急性及び慢性疼痛ならびに炎症及び心血管疾患の症状、脳卒中、心筋梗塞(単独もしくは血栓溶解治療後)、熱傷、成人呼吸窮迫症候群(ARDS)、外傷後の二次的多臓器損傷、急性糸球体腎炎、急性炎症成分を有する皮膚病、急性化膿性髄膜炎又は他の中枢神経系障害、血液透析に関連する症候群、白血球フェレーシス、顆粒球輸血関連症候群、及び壊死性腸炎、合併症、例えば、経皮経管冠動脈形成後の再狭窄、外傷性関節炎、敗血症、慢性閉塞性肺疾患及び鬱血性心不全。
医薬品として使用するとき、本発明の化合物は、典型的には医薬組成物の形態で投与する。そのような組成物は、医薬品分野で周知の手順を用いて調製することができ、少なくとも1個の本発明の化合物を含む。本発明の化合物は、単独で投与しても、あるいは、本発明の化合物の安定性を高め、特定の実施態様において本化合物を含む医薬組成物の投与を促進し、溶解性や分散性を増大させ、阻害活性を増大させ、補助的治療をもたらすなどの補助剤と組み合わせて投与してもよい。本発明の化合物は、単独で用いても、あるいは本発明の他の活性物質と共に、また場合により他の薬理学的に活性な物質と共に用いてもよい。一般に、本発明の化合物は、治療有効量又は薬学的有効量で投与するが、診断目的又は他の目的には、より少量で投与してもよい。
Claims (11)
- 式(I):
[式中、
Hetは、フェニル、オキサゾリル、イソオキサゾリル、オキサジアゾリル、チアゾリル、イソチアゾリル、ピラゾリル、ピロリル、イミダゾリル、ピリジニル、ピリミジニル及びピリダジニル(それぞれ、1〜3個のC1−5アルキル、C1−5アルコキシ、C1−5アシル、C1−5アシルアミノ、アミノ、シアノ、ヒドロキシル又はハロゲンにより場合により置換されている)より選択される環であり;
Xは、−N(R3)−であり;
Yは、N又はCHであり、
Zは、H又はFであり、
R1は、C1−5アルキル、C1−5アルコキシC1−5アルキル、C1−5アルコキシ、C1−5アルコキシカルボニル−(CH2)n−、HOC(=O)−(CH2)n−、ヒドロキシC1−5アルキル、−C(O)NR4R5及びAr1より選択され;
R2は、水素、Ar2−(CH2)n−、ヘテロサイクル及びC1−5アルキルより選択され;
R3は、水素及びC1−5アルキルより選択され;
各R4及びR5は、独立して、水素、C1−5アシル、C1−5アルキル、C1−5アルコキシ、ヒドロキシル、カルボサイクル−(CH2)n−、ヘテロアリール−及びヘテロサイクル−(CH2)n−より選択され;
Ar1は、カルボサイクル、ヘテロアリール及びヘテロサイクル(ここで、Ar1は、1〜3個のC1−5アルキル、C1−5アルコキシ、C1−5アシル、C1−5アシルアミノ、アミノ、シアノ、ヒドロキシル又はハロゲンにより場合により置換されている)より選択され;
Ar2は、カルボサイクル、ヘテロアリール及びヘテロサイクル(ここで、Ar2は、1〜3個のヘテロアリール、C1−5アルキル、C1−5アルコキシ−(CH2)n−、C1−5アルコキシカルボニル−(CH2)n−、カルボキシ−(CH2)n−、C1−5アシル、C1−5アシルアミノ、アミノ、シアノ、ヒドロキシル、スルホニル、スルホキシド、チオ、オキソ又はハロゲンにより場合により置換されている)より選択され;
各nは、独立して、0〜2である]で示される化合物、又はその薬学的に許容しうる塩。 - 化合物が、式(II):
[式中、
R1は、C1−5アルコキシC1−5アルキル、C1−5アルコキシカルボニル−(CH2)n−及びAr1より選択され;
R2は、Ar2−(CH2)n−、ヘテロサイクル及びC1−5アルキルより選択され;
R3は、水素及びC1−5アルキルより選択され;
Ar1は、フェニル、オキサゾリル、4,5−ジヒドロ−オキサゾリル、イソオキサゾリル、オキサジアゾリル、チアゾリル、ピラゾリル、ピロリル、イミダゾリル、ピリジニル、ピリミジニル、ピリダジニル及びピラジニル(ここで、Ar1は、1〜3個のC1−5アルキル、C1−5アルコキシ、C1−5アシル、C1−5アシルアミノ、アミノ、シアノ、ヒドロキシル又はハロゲンにより場合により置換されている)より選択され;
Ar2は、フェニル、オキサゾリル、イソオキサゾリル、オキサジアゾリル、フラニル、チオフェニル、トリアゾリル、チアジアゾリル、イソチアゾリル、チアゾリル、ピラゾリル、ピロリル、イミダゾリル、ピリジニル、ピリミジニル、ピリダジニル及びピラジニル(ここで、Ar2は、1〜3個のC1−5アルキル、C1−5アルコキシ−(CH2)n−、C1−5アルコキシカルボニル−(CH2)n−、カルボキシ−(CH2)n−、C1−5アシル、C1−5アシルアミノ、アミノ、シアノ、ヒドロキシル、オキソ又はハロゲンにより場合により置換されている)より選択される]により表される、請求項1に記載の化合物。 - R2が、Ar2−(CH2)n−より選択され;
Ar2が、フェニル、オキサゾリル、イソオキサゾリル、オキサジアゾリル、チアゾリル、ピラゾリル、ピロリル、イミダゾリル、ピリジニル、ピリミジニル、ピリダジニル及びピラジニル(ここで、Ar2は、1〜3個のC1−5アルキル、C1−5アルコキシ−(CH2)n−、C1−5アルコキシカルボニル−(CH2)n−、カルボキシ−(CH2)n−、C1−5アシル、C1−5アシルアミノ、アミノ、シアノ、ヒドロキシル、オキソ又はハロゲンにより場合により置換されている)より選択される、請求項2に記載の化合物。 - Hetが、ピラゾリル、イミダゾリル及びピリジニル(それぞれ、1〜3個のC1−5アルキル、C1−5アルコキシ、C1−5アシル、C1−5アシルアミノ、アミノ、シアノ、ヒドロキシル又はハロゲンにより場合により置換されている)より選択される環であり;
Ar1が、フェニル、オキサゾリル、4,5−ジヒドロ−オキサゾリル、イソオキサゾリル、オキサジアゾリル、ピラゾリル、イミダゾリル、ピリジニル及びピリミジニル(ここで、Ar1は、1〜2個のC1−5アルキル又はハロゲンにより場合により置換されている)より選択され;
Ar2が、フェニル、ピリジニル、ピリミジニル、ピリダジニル及びピラジニル(ここで、Ar2は、1〜3個のC1−5アルキル、C1−5アルコキシ、C1−5アルコキシカルボニル、カルボキシ、又はハロゲンにより場合により置換されている)より選択される、請求項3に記載の化合物。 - Hetが、ピラゾリル、イミダゾリル及びピリジニル(それぞれ、C1−5アルキル、C1−5アルコキシ又はハロゲンにより場合により置換されている)より選択される環であり;
R1が、C1−2アルコキシC1−2アルキル、C1−2アルコキシカルボニル及びAr1より選択され;
R2が、Ar2−CH2−より選択され;
Ar1が、フェニル、4,5−ジヒドロ−オキサゾリル、オキサジアゾリル、ピラゾリル、ピリジニル及びピリミジニル(ここで、Ar1は、1〜2個のC1−3アルキル又はハロゲンにより場合により置換されている)より選択され;
Ar2が、フェニル及びピリジニル(ここで、Ar2は、1〜2個のC1−5アルキル、C1−5アルコキシ、C1−5アルコキシカルボニル、ヒドロキシル、オキソ、カルボキシ、又はハロゲンにより場合により置換されている)より選択される、請求項4に記載の化合物。 - R 1 が、C1−5アルコキシカルボニル−である、請求項7に記載の化合物。
- 治療有効量の請求項1〜9のいずれか一項に記載の化合物ならびに1種以上の薬学的に許容しうる担体及び/又は補助剤を含む医薬組成物。
- 関節リウマチ、変形性関節症、骨粗鬆症、歯周炎、アテローム性動脈硬化、鬱血性心不全、多発性硬化症及び腫瘍転移より選択される疾患を処置するための、請求項10に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10620708P | 2008-10-17 | 2008-10-17 | |
US61/106,207 | 2008-10-17 | ||
PCT/US2009/060436 WO2010045188A1 (en) | 2008-10-17 | 2009-10-13 | Heteroaryl substituted indole compounds useful as mmp-13 inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012505891A JP2012505891A (ja) | 2012-03-08 |
JP2012505891A5 JP2012505891A5 (ja) | 2012-11-29 |
JP5529876B2 true JP5529876B2 (ja) | 2014-06-25 |
Family
ID=41508906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011532175A Active JP5529876B2 (ja) | 2008-10-17 | 2009-10-13 | Mmp−13阻害剤として有用なヘテロアリール置換インドール化合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8785489B2 (ja) |
EP (1) | EP2340243B1 (ja) |
JP (1) | JP5529876B2 (ja) |
CA (1) | CA2738929A1 (ja) |
WO (1) | WO2010045188A1 (ja) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010045190A1 (en) | 2008-10-15 | 2010-04-22 | Boehringer Ingelheim International Gmbh | Fused heteroaryl diamide compounds useful as mmp-13 inhibitors |
US8785489B2 (en) | 2008-10-17 | 2014-07-22 | Boehringer Ingelheim International Gmbh | Heteroaryl substituted indole compounds useful as MMP-13 inhibitors |
EP2346831B1 (en) | 2008-11-17 | 2015-01-07 | Boehringer Ingelheim International GmbH | Heteroaryl diamide compounds useful as mmp-13 inhibitors |
CN102574788A (zh) * | 2009-09-24 | 2012-07-11 | 弗·哈夫曼-拉罗切有限公司 | 作为crac调节剂的吲哚衍生物 |
TWI423962B (zh) * | 2009-10-07 | 2014-01-21 | Lg Life Sciences Ltd | 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物 |
IN2014MN00258A (ja) | 2011-07-15 | 2015-09-25 | Janssen Pharmaceuticals Inc | |
CN106518845B (zh) | 2011-08-30 | 2019-09-13 | Chdi基金会股份有限公司 | 犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法 |
US10266490B2 (en) * | 2012-03-16 | 2019-04-23 | Georgetown University | Radioprotector compounds |
SG10201804021TA (en) | 2013-11-13 | 2018-07-30 | Vertex Pharma | Methods of preparing inhibitors of influenza viruses replication |
US10730866B2 (en) * | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
SG11201700341PA (en) | 2014-07-17 | 2017-02-27 | Chdi Foundation Inc | Methods and compositions for treating hiv-related disorders |
WO2016026078A1 (en) * | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
US9938273B2 (en) | 2015-12-07 | 2018-04-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2017165139A1 (en) | 2016-03-25 | 2017-09-28 | St. Jude Children's Research Hospital | 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane x receptor |
US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
US11180474B2 (en) | 2016-07-30 | 2021-11-23 | Bristol-Myers Squibb Company | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors |
EP3510024B1 (en) | 2016-09-09 | 2021-11-17 | Bristol-Myers Squibb Company | Pyridyl substituted indole compounds |
US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
JP7104775B2 (ja) | 2017-08-04 | 2022-07-21 | ブリストル-マイヤーズ スクイブ カンパニー | Tlr7/8/9の阻害剤として有用な置換インドール化合物 |
KR20200036913A (ko) | 2017-08-04 | 2020-04-07 | 브리스톨-마이어스 스큅 컴퍼니 | [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물 |
KR20200086709A (ko) | 2017-11-14 | 2020-07-17 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 인돌 화합물 |
FI3728252T3 (fi) | 2017-12-18 | 2023-10-18 | Bristol Myers Squibb Co | 4-atsaindoliyhdisteitä |
EP3728253B1 (en) | 2017-12-19 | 2024-03-27 | Bristol-Myers Squibb Company | 6-azaindole compounds |
AU2018390820A1 (en) | 2017-12-19 | 2020-08-06 | Bristol-Myers Squibb Company | Substituted indole compounds useful as TLR inhibitors |
BR112020011979A2 (pt) | 2017-12-19 | 2020-11-17 | Bristol-Myers Squibb Company | compostos de indol substituídos por amida úteis como inibidores de tlr |
CA3085942A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Aryl and heteroaryl substituted indole compounds |
CA3085937A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Diazaindole compounds |
ES2904676T3 (es) | 2017-12-20 | 2022-04-05 | Bristol Myers Squibb Co | Compuestos de amino indol útiles como inhibidores de TLR |
EP3628669A1 (en) * | 2018-09-28 | 2020-04-01 | GenKyoTex Suisse SA | Novel compounds as nadph oxidase inhibitors |
KR20220097434A (ko) * | 2019-11-01 | 2022-07-07 | 브리스톨-마이어스 스큅 컴퍼니 | 톨 수용체 억제제로서의 치환된 피라졸 화합물 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08151380A (ja) * | 1994-11-29 | 1996-06-11 | Kyorin Pharmaceut Co Ltd | ビス(トリフルオロメチルピロロインドールカルボン酸エステル)誘導体及びその製造方法 |
AU2039800A (en) | 1998-12-04 | 2000-06-26 | Ontogen Corporation | 5-membered heterocycles for the treatment of human diseases involving modulatorsof selectins |
GB0018758D0 (en) | 2000-07-31 | 2000-09-20 | Smithkline Beecham Plc | Novel use and compunds |
MXPA03000923A (es) | 2000-07-31 | 2003-06-09 | Smithkline Beecham Plc | Compuestos de carboxamida y su uso como antagonistas de un receptor 11cby humano. |
WO2002016348A1 (en) | 2000-08-09 | 2002-02-28 | Astrazeneca Ab | Antiangiogenic bicyclic derivatives |
WO2003020699A2 (en) * | 2001-08-30 | 2003-03-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
EP1501514B1 (en) * | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
DE10229070A1 (de) | 2002-06-28 | 2004-01-15 | Merck Patent Gmbh | Phenylderivate 5 |
CA2525502C (en) | 2003-05-21 | 2012-12-18 | Prosidion Limited | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase |
JP2007528362A (ja) | 2003-08-14 | 2007-10-11 | 旭化成ファーマ株式会社 | 置換アリールアルカン酸誘導体及びその用途 |
CA2574237A1 (en) | 2004-07-20 | 2006-01-26 | Siena Biotech S.P.A. | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof |
MX2007006790A (es) * | 2004-12-07 | 2007-08-15 | Toyama Chemical Co Ltd | Novedosos derivado de acido antranilico o sal del mismo. |
EP1838690A2 (en) | 2004-12-21 | 2007-10-03 | Devgen N.V. | Compounds with kv4 ion channel activity |
GT200600042A (es) | 2005-02-10 | 2006-09-27 | Aventis Pharma Inc | Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a |
SI1860098T1 (sl) * | 2005-03-16 | 2013-03-29 | Toyama Chemical Co., Ltd. | Nov derivat antranilne kisline ali sol le-tega |
US20060235037A1 (en) * | 2005-04-15 | 2006-10-19 | Purandare Ashok V | Heterocyclic inhibitors of protein arginine methyl transferases |
JP2009504761A (ja) | 2005-08-19 | 2009-02-05 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | 睡眠剤と置換ビスアリール及びヘテロアリール化合物の組み合わせ物及び治療でのその使用 |
EP2002834A1 (de) * | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors |
WO2010045190A1 (en) | 2008-10-15 | 2010-04-22 | Boehringer Ingelheim International Gmbh | Fused heteroaryl diamide compounds useful as mmp-13 inhibitors |
US8785489B2 (en) | 2008-10-17 | 2014-07-22 | Boehringer Ingelheim International Gmbh | Heteroaryl substituted indole compounds useful as MMP-13 inhibitors |
EP2346831B1 (en) | 2008-11-17 | 2015-01-07 | Boehringer Ingelheim International GmbH | Heteroaryl diamide compounds useful as mmp-13 inhibitors |
-
2009
- 2009-10-13 US US13/123,048 patent/US8785489B2/en active Active
- 2009-10-13 CA CA2738929A patent/CA2738929A1/en not_active Abandoned
- 2009-10-13 JP JP2011532175A patent/JP5529876B2/ja active Active
- 2009-10-13 EP EP09740801.7A patent/EP2340243B1/en active Active
- 2009-10-13 WO PCT/US2009/060436 patent/WO2010045188A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CA2738929A1 (en) | 2010-04-22 |
US20110275631A1 (en) | 2011-11-10 |
EP2340243B1 (en) | 2014-10-08 |
JP2012505891A (ja) | 2012-03-08 |
EP2340243A1 (en) | 2011-07-06 |
US8785489B2 (en) | 2014-07-22 |
WO2010045188A1 (en) | 2010-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5529876B2 (ja) | Mmp−13阻害剤として有用なヘテロアリール置換インドール化合物 | |
JP5507567B2 (ja) | Ccr1受容体拮抗薬としてのアザインダゾール化合物 | |
JP5642963B2 (ja) | ピリジノニルpdk1阻害剤 | |
JP6527147B2 (ja) | 血漿カリクレインの阻害薬 | |
JP6759100B2 (ja) | 治療用阻害化合物 | |
US8436011B2 (en) | Pyridinopyridinone derivatives, preparation thereof and therapeutic use thereof | |
EP2152674B1 (en) | Benzimidazolone chymase inhibitors | |
JP2019019144A (ja) | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 | |
EP1957491A2 (en) | Pyrrolo (2,3-b) pyridine derivatives useful as tec kinase inhibitors | |
JP2009517383A (ja) | 新規な3−ビシクロカルボニルアミノピリジン−2−カルボキサミド又は3−ビシクロカルボニルアミノピラジン−2−カルボキサミド | |
US8481538B2 (en) | Heterocyclic inhibitors of c-Met and uses thereof | |
CA2782588A1 (en) | Nitrogen-containing heteroaryl derivatives | |
JP2022532719A (ja) | Acss2阻害剤およびその使用方法 | |
TWI762534B (zh) | 作為PI3Kδ抑制劑的咪唑並[1,5-A]吡衍生物 | |
AU2010308277A1 (en) | Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists | |
WO2020038460A1 (zh) | 一种新型的喹啉衍生物抑制剂 | |
WO2009140101A2 (en) | Imidazopyridine compounds useful as mmp-13 inhibitors | |
JP5584696B2 (ja) | Mmp−13阻害剤として有用なヘテロアリールジアミド化合物 | |
US8338367B2 (en) | Fused heteroaryl diamide compounds useful as MMP-13 inhibitors | |
WO2008098096A1 (en) | Anti-cytokine heterocyclic compounds | |
KR101746199B1 (ko) | 질소 함유 헤테로아릴 유도체 및 GSK3β 저해제로서의 이의 용도 | |
EP4036086A1 (en) | Heterocyclic derivative and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121012 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121012 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20131212 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140314 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140408 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140417 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5529876 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |